Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Negative Cash Flow ⢠Short-Term Debt CYRX's strong liquidity and cash coverage provide balance-sheet support, but weak operating profitability, negative cash flow, and heavy short-term debt make the investment case high-risk.
Price Behavior
Key Price Behavior Insights: ⢠Modest net gain ⢠Momentum weakened ⢠Range-bound trading Support Level: $15.50â$15.55 Resistance Level: $16.00â$16.10 CYRX was neutral-to-modestly bullish last month, with support at $15.50 and a reclaim of $16.10 needed to target higher resistance, while a break below $15.50 raises downside risk.
Sentiment & News
Key News Insights: ⢠Revenue growth ⢠EBITDA positive ⢠Buy upgrade CryoPort's Q2 growth, positive adjusted EBITDA, and raised optimism signal improving momentum despite a continued net loss.
AI Summary
CYRX's investment case has shifted to proving operating leverage: diversified service growth and positive adjusted EBITDA are encouraging, but investors should wait for sustained EBITDA margin expansion and improving free cash flow before underwriting the current valuation, particularly with $190M of near-term debt.
Description
Cryoport, Inc. provides temperature-controlled logistics and related services for life sciences customers across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Its offerings include shipment management software, condition-monitoring and tracking tools, cryogenic transport equipment, and storage and handling services for biological materials. The company serves the biopharma, animal health, and human reproductive medicine markets and was founded in 1999 in Brentwood, Tennessee.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | CYRX | Cryoport, Inc. | Q1 2026 revenue grew 16% YoY, commercial cell and gene therapy revenue grew 26%, full-year revenue guidance was raised to $192M-$196M, and the stock is up about 37% over 21 trading days. | Closed | +4.4% |